Journal
BIOSENSORS & BIOELECTRONICS
Volume 96, Issue -, Pages 373-380Publisher
ELSEVIER ADVANCED TECHNOLOGY
DOI: 10.1016/j.bios.2017.02.011
Keywords
Polyoxazolines; Plasma polymers; Cancer cell capture; Urine; Diagnostic devices
Categories
Funding
- Channel 7 Children Research Foundation [15976]
- South Australian State Government Premier Research and Industry Fund Grant
- UniSA Research Theme Investment Scheme Grant
- NHMRC [APP1122825]
Ask authors/readers for more resources
Urothelial cancers are amongst the 10 most common types of cancer and represent a major health problem worldwide. Current urinary diagnostic tests for urothelial cancer are expensive and have limited sensitivity and specificity. In this work, proofs of concept for a selective cancer cell capture platform are presented with the aim to achieve the first generation of specific urinary tests for the detection of cancer cells in urine specimen. The unique reactivity of plasma deposited polyoxazoline was used to covalently bind cancer specific antibodies in microchannels. Cancer cells dispersed in patient urine were successfully captured with up to 99% selectivity and 100% sensitivity over a wide range of cell concentrations. The streamlined two steps preparation process of the capture platform represents an important advance in medical diagnostics, with broader potential applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available